Isap Biotechnology

Isap Biotech is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of innovative conjugate drugs. The company leverages its proprietary "In Vivo Self Assembly" (IVSA) nanobiotechnology platform and an advanced peptide design platform to create next-generation therapeutics and imaging agents. Its lead candidate, iSAP-0909, is a first-in-class pan-tumor fluorescent imaging agent targeting XIAP, currently in Phase 1 clinical trials for bladder cancer and other solid tumors. The company's pipeline also includes iSAP-0913, a HER2-targeted peptide-drug conjugate (PDC) designed to overcome resistance to existing antibody-drug conjugates (ADCs), and iSAP-1017 for diabetic macular edema. Isap Biotech aims to address significant unmet medical needs in oncology and ophthalmology through its unique self-assembling peptide technology.